Logo image of FGEN

FIBROGEN INC (FGEN) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:FGEN - US31572Q8814 - Common Stock

8.43 USD
-0.13 (-1.52%)
Last: 12/23/2025, 4:30:00 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to FGEN. FGEN was compared to 530 industry peers in the Biotechnology industry. FGEN has a bad profitability rating. Also its financial health evaluation is rather negative. FGEN is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year FGEN was profitable.
FGEN had a negative operating cash flow in the past year.
In the past 5 years FGEN always reported negative net income.
FGEN had negative operating cash flow in 4 of the past 5 years.
FGEN Yearly Net Income VS EBIT VS OCF VS FCFFGEN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M

1.2 Ratios

The Return On Assets of FGEN (157.40%) is better than 99.62% of its industry peers.
Industry RankSector Rank
ROA 157.4%
ROE N/A
ROIC N/A
ROA(3y)-45.81%
ROA(5y)-39.56%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
FGEN Yearly ROA, ROE, ROICFGEN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K

1.3 Margins

FGEN has a better Profit Margin (2598.87%) than 99.62% of its industry peers.
With an excellent Gross Margin value of 345.69%, FGEN belongs to the best of the industry, outperforming 99.43% of the companies in the same industry.
In the last couple of years the Gross Margin of FGEN has declined.
Industry RankSector Rank
OM N/A
PM (TTM) 2598.87%
GM 345.69%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.51%
GM growth 5Y-13.76%
FGEN Yearly Profit, Operating, Gross MarginsFGEN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

More info and screens

2

2. Health

2.1 Basic Checks

FGEN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, FGEN has more shares outstanding
The number of shares outstanding for FGEN has been increased compared to 5 years ago.
Compared to 1 year ago, FGEN has a worse debt to assets ratio.
FGEN Yearly Shares OutstandingFGEN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M
FGEN Yearly Total Debt VS Total AssetsFGEN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

Based on the Altman-Z score of -19.19, we must say that FGEN is in the distress zone and has some risk of bankruptcy.
FGEN's Altman-Z score of -19.19 is on the low side compared to the rest of the industry. FGEN is outperformed by 83.58% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -19.19
ROIC/WACCN/A
WACC14.65%
FGEN Yearly LT Debt VS Equity VS FCFFGEN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

A Current Ratio of 3.71 indicates that FGEN has no problem at all paying its short term obligations.
FGEN has a Current ratio (3.71) which is in line with its industry peers.
A Quick Ratio of 3.60 indicates that FGEN has no problem at all paying its short term obligations.
FGEN has a Quick ratio (3.60) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.71
Quick Ratio 3.6
FGEN Yearly Current Assets VS Current LiabilitesFGEN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

4

3. Growth

3.1 Past

FGEN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 102.02%, which is quite impressive.
Looking at the last year, FGEN shows a very negative growth in Revenue. The Revenue has decreased by -95.39% in the last year.
FGEN shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -35.07% yearly.
EPS 1Y (TTM)102.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%23.53%
Revenue 1Y (TTM)-95.39%
Revenue growth 3Y-49.88%
Revenue growth 5Y-35.07%
Sales Q2Q%-97.68%

3.2 Future

Based on estimates for the next years, FGEN will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.11% on average per year.
The Revenue is expected to grow by 9.58% on average over the next years. This is quite good.
EPS Next Y52.49%
EPS Next 2Y-0.78%
EPS Next 3Y3.05%
EPS Next 5Y15.11%
Revenue Next Year-96.23%
Revenue Next 2Y-81.45%
Revenue Next 3Y-67.47%
Revenue Next 5Y9.58%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
FGEN Yearly Revenue VS EstimatesFGEN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M 150M 200M 250M
FGEN Yearly EPS VS EstimatesFGEN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -20 -40 -60 -80

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 13.60 indicates a correct valuation of FGEN.
96.60% of the companies in the same industry are more expensive than FGEN, based on the Price/Earnings ratio.
FGEN's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 26.61.
FGEN is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE 13.6
Fwd PE N/A
FGEN Price Earnings VS Forward Price EarningsFGEN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FGEN Per share dataFGEN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)0.26
PEG (5Y)N/A
EPS Next 2Y-0.78%
EPS Next 3Y3.05%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for FGEN!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

FIBROGEN INC

NASDAQ:FGEN (12/23/2025, 4:30:00 PM)

8.43

-0.13 (-1.52%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10 2025-11-10/amc
Earnings (Next)03-16 2026-03-16/amc
Inst Owners28.21%
Inst Owner Change5.48%
Ins Owners1.5%
Ins Owner Change0.03%
Market Cap34.14M
Revenue(TTM)8.30M
Net Income(TTM)215.65M
Analysts80
Price Target43.86 (420.28%)
Short Float %3.41%
Short Ratio3.8
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)20.24%
Min EPS beat(2)20.04%
Max EPS beat(2)20.44%
EPS beat(4)4
Avg EPS beat(4)102.91%
Min EPS beat(4)20.04%
Max EPS beat(4)226.05%
EPS beat(8)7
Avg EPS beat(8)62.43%
EPS beat(12)9
Avg EPS beat(12)43.37%
EPS beat(16)11
Avg EPS beat(16)26.6%
Revenue beat(2)0
Avg Revenue beat(2)-42.72%
Min Revenue beat(2)-49.76%
Max Revenue beat(2)-35.68%
Revenue beat(4)2
Avg Revenue beat(4)22.7%
Min Revenue beat(4)-49.76%
Max Revenue beat(4)98.39%
Revenue beat(8)5
Avg Revenue beat(8)22.82%
Revenue beat(12)9
Avg Revenue beat(12)22.18%
Revenue beat(16)10
Avg Revenue beat(16)15.07%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-4.32%
EPS NQ rev (3m)-4.32%
EPS NY rev (1m)0%
EPS NY rev (3m)-307.81%
Revenue NQ rev (1m)0.29%
Revenue NQ rev (3m)0.29%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 13.6
Fwd PE N/A
P/S 4.11
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)0.62
EY7.35%
EPS(NY)-12.19
Fwd EYN/A
FCF(TTM)-4.22
FCFYN/A
OCF(TTM)-4.18
OCFYN/A
SpS2.05
BVpS-4.2
TBVpS-4.2
PEG (NY)0.26
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 157.4%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 2598.87%
GM 345.69%
FCFM N/A
ROA(3y)-45.81%
ROA(5y)-39.56%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.51%
GM growth 5Y-13.76%
F-Score5
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 16.39%
Cap/Sales 2.16%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.71
Quick Ratio 3.6
Altman-Z -19.19
F-Score5
WACC14.65%
ROIC/WACCN/A
Cap/Depr(3y)133.57%
Cap/Depr(5y)124.53%
Cap/Sales(3y)11.27%
Cap/Sales(5y)9.78%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)102.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%23.53%
EPS Next Y52.49%
EPS Next 2Y-0.78%
EPS Next 3Y3.05%
EPS Next 5Y15.11%
Revenue 1Y (TTM)-95.39%
Revenue growth 3Y-49.88%
Revenue growth 5Y-35.07%
Sales Q2Q%-97.68%
Revenue Next Year-96.23%
Revenue Next 2Y-81.45%
Revenue Next 3Y-67.47%
Revenue Next 5Y9.58%
EBIT growth 1Y-29.85%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year20.35%
EBIT Next 3Y7.86%
EBIT Next 5Y4.1%
FCF growth 1Y95.14%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y95.16%
OCF growth 3YN/A
OCF growth 5YN/A

FIBROGEN INC / FGEN FAQ

What is the ChartMill fundamental rating of FIBROGEN INC (FGEN) stock?

ChartMill assigns a fundamental rating of 3 / 10 to FGEN.


Can you provide the valuation status for FIBROGEN INC?

ChartMill assigns a valuation rating of 3 / 10 to FIBROGEN INC (FGEN). This can be considered as Overvalued.


What is the profitability of FGEN stock?

FIBROGEN INC (FGEN) has a profitability rating of 3 / 10.


What is the financial health of FIBROGEN INC (FGEN) stock?

The financial health rating of FIBROGEN INC (FGEN) is 2 / 10.


What is the earnings growth outlook for FIBROGEN INC?

The Earnings per Share (EPS) of FIBROGEN INC (FGEN) is expected to grow by 52.49% in the next year.